Erlotinib is a new generation antitumor drug, a powerful inhibitor of epidermal growth factor receptor tyrosine kinase, which is responsible for the process of intracellular phosphorylation of epidermal growth factor, the expression of which is observed on the surface of both normal and tumor cells. Inhibition of phosphotyrosine receptors of the epidermal factor inhibits the growth of tumor cell lines and / or leads to their death. You can Buy Erlonat ( Erlotinib 150mg ) which is a anticancer medicine from India. Erlonat is generic (equivalent) of the original drug Tarceva.
Erlotinib instructions for use
Eronat used in:
– locally advanced or metastatic non-small cell lung cancer after failure of one or more chemotherapy regimens;
– inoperable locally advanced or metastatic pancreatic cancer as therapy 1-St line in combination with gemcitabine.
The drug is taken orally 1 p / day for at least 1 hour before or after 2 hours after meals. With non-small cell lung cancer, the drug is prescribed 150 mg daily, for a long time.
In pancreatic cancer, 100 mg daily, long in combination with gemcitabine. When signs of progression of the disease therapy should be discontinued. Caution should be prescribed to patients with impaired liver function. Safety and efficacy in patients with hepatic insufficiency, renal impairment and patients under the age of 18 years have not been studied. If necessary, the correction dose is recommended to be reduced gradually, each time by 50 mg.
Side effects include:
On PS: anorexia, diarrhea, vomiting, stomatitis, dyspepsia, abdominal pain; gastrointestinal bleeding (some of which were associated with the simultaneous use of warfarin or NSAIDs), impaired liver function (including increased ALT, ACT, bilirubin), mostly transient, mild to moderate severity or associated with liver metastases.
From the organ of vision: conjunctivitis, dry keratoconjunctivitis; keratitis, a case of transition into the corneal ulcer.
From DS: cough, dyspnea; epistaxis; interstitial lung disease (interstitial pneumonia, obliterative bronchiolitis, pulmonary fibrosis, acute respiratory distress syndrome and pulmonary infiltration, including cases with fatal outcome).
CNS and peripheral NS: headache, neuropathy, depression.
Dermatological reactions: rash, alopecia, dry skin, itching.
Other: fever, fatigue, chills, severe infections (with or without neutropenia), pneumonia, sepsis, fibrous inflammation of the subcutaneous tissue, weight loss.
To use the drug: pregnancy; lactation; hypersensitivity to erlotinib or to any component of the drug. With caution, the drug should be prescribed for impaired liver function, patients under the age of 18 years.
The use of erlotinib with other drugs can lead to the following consequences: inhibitors of CYP3A4 isoenzyme (ketoconazole, etc.) reduce the metabolism of erlotinib and increase its concentration in plasma; inducers of CYP3A4 isoenzyme (rifampicin, etc.) increase the metabolism of erlotinib and significantly reduce its concentration in plasma. With the simultaneous use of erlotinib with warfarin and other coumarin derivatives, there was an increase in MHO and bleeding, including gastrointestinal bleeding, some of which were associated with the introduction of warfarin.
Store the drug should be in a dry, protected from the sun and out of reach of children, at a temperature of 15 to 30°C. date of manufacture and shelf life are indicated on the package.